Using large-scale data from Iceland and the UK Biobank, it was demonstrated that specific low-frequency coding variants in RPL3L elevate the risk of atrial fibrillation, which could also been observed in distinct DCM patients with biallelic pathogenic variants in RPL3L, highlighting the crucial role of RPL3L in cardiac-related processes [45, 64]. This evidence concerns the gene RPL3L and atrial fibrillation.